发明授权
EP2542257B1 OPTIMIZED MONOCLONAL ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR (TFPI)
有权
优化的单克隆抗体对组织因子途径抑制剂（TFPI）
- 专利标题： OPTIMIZED MONOCLONAL ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR (TFPI)
- 专利标题（中）： 优化的单克隆抗体对组织因子途径抑制剂（TFPI）
-
申请号： EP11751244.2申请日： 2011-03-01
-
公开(公告)号： EP2542257B1公开(公告)日： 2017-07-05
- 发明人: SCHOLZ, Peter , WANG, Zhuozhi , PAN, Junliang , GRUDZINSKA, Joanna , VOTSMEIER, Christian , TEBBE, Jan , BIRKENFELD, Jörg , WOBST, Nina , BRÜCKNER, Simone , STEINIG, Susanne
- 申请人： Bayer Healthcare LLC
- 申请人地址： 100 Bayer Boulevard P.O. Box 915 Whippany, NJ 07981 US
- 专利权人： Bayer Healthcare LLC
- 当前专利权人： Bayer Healthcare LLC
- 当前专利权人地址： 100 Bayer Boulevard P.O. Box 915 Whippany, NJ 07981 US
- 代理机构： BIP Patents
- 优先权： US309290P 20100301
- 国际公布： WO2011109452 20110909
- 主分类号： C07K16/38
- IPC分类号： C07K16/38 ; A61K39/00 ; A61K39/395
摘要：
Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.
公开/授权文献
信息查询
